Tymlos Label Update Highlights Bone Building Mechanism of Action
The update is based on data from an open-label, single-arm histomorphometry study.
The update is based on data from an open-label, single-arm histomorphometry study.
The network meta-analysis compared the effects of 9 osteoporosis drugs on BMD.
The revisions are based on a completed review of a large randomized safety clinical trial, which included 4362 patients with rheumatoid arthritis.
EDG-5506 is a selective, small molecule myosin inhibitor designed to protect injury-susceptible fast skeletal muscle fibers.
The indication for adult upper limb spasticity treatment now includes elbow and forearm muscles, intrinsic hand muscles, and thumb muscles.
Small increases in the risk for statin-associated muscle symptoms were observed for patients on high-intensity therapy.
Researchers compared the effectiveness of full-length vs brief mindfulness training programs for improving anxiety among patients with rheumatic disease.
Apitegromab is a selective inhibitor of the inactive form of myostatin to block its activation in the muscle.
Losmapimod is a selective p38α/β mitogen activated protein kinase inhibitor that works by reducing the expression of the DUX4 gene in muscle cells.
About half of U.K. patients experienced an increase in symptoms during early stages of the pandemic